A phase II trial of oral panobinostat (LBH589), a no deacetylase inhibitor (DACi) in patients with primary myelofibrosis (PMF), post-essential thrombocythemia (ET) myelofibrosis, and post-polycythemia vera (PV) myelofibrosis

被引：1
|
作者：
DeAngelo, D. J.
Tefferi, A.
Mesa, R. A.
Paley, C. S.
Wadleigh, M.
Snyder, D.
Ondovik, M. S.
Rine, J.
Bhalla, K. N.
机构：
[1] Harvard Univ, Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Mayo Clin Rochester, Rochester, MN USA
[3] Mayo Clin Arizona, Scottsdale, AZ USA
[4] Novartis Pharmaceut, E Hanover, NJ USA
[5] City Hope Natl Med Ctr, Duarte, CA USA
[6] Med Coll Georgia, Ctr Canc, Augusta, GA 30912 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.tps283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS283
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Novel findings of splenic extramedullary hematopoiesis during primary myelofibrosis, post-essential thrombocythemia, and post-polycythemia vera myelofibrosis
    Alexandre Guy
    Audrey Bidet
    Catherine Ling
    Charline Caumont
    Lisa Boureau
    Jean-François Viallard
    Marie Parrens
    Virchows Archiv, 2021, 479 : 755 - 764
  • [22] Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (postPV MF), or Post-Essential Thrombocythemia Myelofibrosis (postET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen K.
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Rivera, Candido E.
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2016, 128 (22)
  • [23] COMPASSIONATE USE PROGRAM (CUP) WITH RUXOLITINIB IN PATIENTS WITH PRIMARY MYELOFIBROSIS (PMF), POST-POLYCYTHEMIA VERA MYELOFIBROSIS (PPV-MF), AND POST-ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS (PET-MF)
    Vargas, P.
    Karpovitch, X.
    Alvarado, M.
    Ovilla, R.
    Agreda, G.
    Guzman, P.
    Solis, J.
    Kassack, J.
    Silva, S.
    Zavala, S.
    Morales, J.
    Herrera, A.
    Reynoso, E.
    Rodriguez, M.
    Ruiz, G.
    Sobrevilla, P.
    Garcia, M.
    Aguilar, C.
    Morales, R.
    Barrera, E.
    Osuna, A.
    Carrillo, R.
    Silos, G.
    Vega, A.
    Cuin, S.
    Mora, M.
    Best, C.
    Murillo, E.
    Loarca, L.
    Perez, O.
    Salazar, J.
    Baez, E.
    Montemayor, J.
    Barrera, D.
    Garcia, J.
    Peraza, L.
    Baltazar, S.
    Iniguez, L.
    Oseguera, R.
    Nacho, K.
    Romero, T.
    HAEMATOLOGICA, 2013, 98 : 765 - 766
  • [24] A Phase 1/2 Study of NS-018, an Oral JAK2 Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (pPV MF), or Post-Essential Thrombocythemia Myelofibrosis (pET MF)
    Verstovsek, Srdan
    Talpaz, Moshe
    Ritchie, Ellen
    Wadleigh, Martha
    Odenike, Olatoyosi
    Jamieson, Catriona
    Stein, Brady
    Uno, Tomonori
    Mesa, Ruben A.
    BLOOD, 2015, 126 (23)
  • [25] Clinical Associations of Cytogenetic Abnormalities in Patients with Primary and Post-Essential Thrombocythemia and Post-Polycythemia Vera Myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Pemmaraju, Naveen
    Newberry, Kate J.
    Bueso-Ramos, Carlos E.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [26] Cytogenetic Risk Stratification in Primary Versus Post-Essential Thrombocythemia / Post-Polycythemia Vera Myelofibrosis
    Masarova, Lucia
    Bose, Prithviraj
    Daver, Naval G.
    Pemmaraju, Naveen
    Newberry, Kate J.
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2016, 128 (22)
  • [27] Phase II Study of Sunitinib in Patients With Primary or Post-Polycythemia Vera/Essential Thrombocythemia Myelofibrosis
    Apostolidou, Effrosyni
    Kantarjian, Hagop
    Thomas, Deborah
    Burger, Ian
    Borthakur, Gautam
    Verstovsek, Srdan
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2010, 10 (04): : 281 - 284
  • [28] Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center
    Masarova, Lucia
    Bose, Prithviraj
    Pemmaraju, Naveen
    Daver, Naval
    Cortes, Jorge E.
    Estrov, Zeev
    Kantarjian, Hagop M.
    Verstovsek, Srdan
    BLOOD, 2017, 130
  • [29] Solid Tumors in Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: A Study on 2220 Patients
    Mora, Barbara
    Rumi, Elisa
    Guglielmelli, Paola
    Barraco, Daniela
    Maffioli, Margherita
    Rambaldi, Alessandro
    Caramella, Marianna
    Komrokji, Rami S.
    Gotlib, Jason R.
    Kiladjian, Jean-Jacques
    Cervantes, Francisco
    Devos, Timothy
    Palandri, Francesca
    De Stefano, Valerio
    Ruggeri, Marco
    Silver, Richard T.
    Benevolo, Giulia
    Albano, Francesco
    Cavalloni, Chiara
    Pietra, Daniela
    Barbui, Tiziano
    Rotunno, Giada
    Cazzola, Mario
    Vannucchi, Alessandro M.
    Giorgino, Toni
    Passamonti, Francesco
    BLOOD, 2018, 132
  • [30] Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients
    Mora, Barbara
    Guglielmelli, Paola
    Kuykendall, Andrew
    Rumi, Elisa
    Maffioli, Margherita
    Palandri, Francesca
    De Stefano, Valerio
    Caramella, Marianna
    Salmoiraghi, Silvia
    Kiladjian, Jean-Jacques
    Gotlib, Jason
    Iurlo, Alessandra
    Cervantes, Francisco
    Ruggeri, Marco
    Silver, Richard T.
    Albano, Francesco
    Benevolo, Giulia
    Ross, David M.
    Della Porta, Matteo G.
    Devos, Timothy
    Rotunno, Giada
    Komrokji, Rami S.
    Casetti, Ilaria C.
    Merli, Michele
    Brociner, Marco
    Caramazza, Domenica
    Auteri, Giuseppe
    Barbui, Tiziano
    Cattaneo, Daniele
    Bertu, Lorenza
    Arcaini, Luca
    Vannucchi, Alessandro M.
    Passamonti, Francesco
    LEUKEMIA, 2022, 36 (10) : 2453 - 2460
12345